Oppositional Defiant Disorder and Aggression in a Young Man with Mental Retardation: Long-Term Treatment in a Community-Based Setting

A longitudinal, intensive treatment program is described that was implemented over an 8-year period in a community-based setting for a young man with mental retardation and oppositional defiant disorder with severe physical aggression. The development of this disorder and its systematic treatment are described, with new components added based on improvement in the individual’s behavior. The individual made steady progress and has maintained good behavioral stability for the final three years of the treatment program. This paper highlights the inherent difficulties of applying empirically validated treatment strategies in community-based settings

Inflammatory biomarkers in Alzheimer's disease plasma

Plasma biomarkers for Alzheimer's disease (AD) diagnosis/stratification are a "Holy Grail" of AD research and intensively sought; however, there are no well-established plasma markers. A hypothesis-led plasma biomarker search was conducted in the context of international multicenter studies. The discovery phase measured 53 inflammatory proteins in elderly control (CTL; 259), mild cognitive impairment (MCI; 199), and AD (262) subjects from AddNeuroMed. Ten analytes showed significant intergroup differences. Logistic regression identified five (FB, FH, sCR1, MCP-1, eotaxin-1) that, age/APOε4 adjusted, optimally differentiated AD and CTL (AUC: 0.79), and three (sCR1, MCP-1, eotaxin-1) that optimally differentiated AD and MCI (AUC: 0.74). These models replicated in an independent cohort (EMIF; AUC 0.81 and 0.67). Two analytes (FB, FH) plus age predicted MCI progression to AD (AUC: 0.71). Plasma markers of inflammation and complement dysregulation support diagnosis and outcome prediction in AD and MCI. Further replication is needed before clinical translation